Navigation Links
ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
Date:5/20/2009

HALIFAX, May 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced a collaboration agreement with the National Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic. This collaboration will develop new 3-D MRI technology to track the effect of IVT's DepoVax(TM) technology on reducing tumour growth.

"This research has the potential to deliver extremely sensitive MRI analysis, down to the individual cell level, and we will see, for the first time, our DepoVax(TM) formulation in action," remarked Dr. Marc Mansour, vice president R&D at IVT.

In pre-clinical studies, IVT has shown that DepoVax(TM) vaccines can eradicate cancerous tumors. This new research involves labeling liposomes, suspended in the DepoVax(TM) formulation, with iron-oxide nanoparticles. The 3-D MRI analysis will shed light on the activity of DepoVax(TM) in vivo, and allow the monitoring of tumor elimination in real time.

Current MRI techniques are well established in biomedical research. This research aims at developing highly sensitive and quantitative techniques for monitoring tumor progression and vaccine clearance in vivo.

"This collaboration means that NRC-IBD Atlantic will break new ground in developing novel MRI imaging techniques that will vastly improve the quality of information that may be acquired non-invasively," continued Mansour.

ABOUT IVT

Most recently, ImmunoVaccine Technologies presented significant advancements in its therapeutic cancer, pandemic influenza and Hepatitis B vaccine applications at BIO 2009 international convention www.convention.bio.org.

ImmunoVaccine Technologies Inc., is a privately held, vaccine development company. Through its own biotech research, patented DepoVax(TM) technology, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. www.immunovaccine.com.


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
3. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
4. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... March 20, 2017 , ... SSCI and Whitehouse Laboratories, divisions of ... 2017 ! Sponsored by the Parenteral Drug Association (PDA), the New York Interphex ... industry professionals in attendance and more than 625 exhibitors, the educational and networking opportunities ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen ... today announced that it has entered into an exclusive global license agreement with ... disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and ...
(Date:3/20/2017)... ... ... The fourth annual Hackaday Prize , which aims to expand the ... lives, launches today. Sponsored by Digi-Key and Microchip , the competition ... prizes to engineers, inventors and tinkerers who “build something that matters.” , The first ...
(Date:3/20/2017)... PUYALLUP, Wash. , March 20, 2017 ... leading provider of ethical review of clinical research, announced ... Review Solution TM (SRS) for NIH-funded multi-site ... among its 2,300 institution clients, WIRB has an extensive ... upon our trusted status as the IRB of record ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):